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Pharmacokinetics and Fibrin Specificity of Alteplase During
Accelerated Infusions in Acute Myocardial Infarction
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Biberach. GSrtinyen and Ulm, Germany
Phatmecokinetics and fibrin specificity of alteptase (recombinant
thane-type
plasminogen activator) were determined in IO patients
with made, myorard td infarction undergoing as aorelers •^t alz-
sion regimen during the alteplaselaniatreplase potency study
(TAPS). Fifteen milligrams of alteplase was a dministered as an
intravenous halos injection, fdNowed by infisims of 50 mg over
30 min and 35 mg over a farther 60 min .
Mean steady state plasma concentration; of alteplase during
the initial
30 minwen
3.2 m 0.84 µglnel, measured immaisadom-
leally, and 2.1 a 0.23 uglml, measured using a functional activity
assay
. These vatnts were 45% and 51 % higher, respectively, than
those during the s?amlard infusion schedule (p < 0,01) . Iiowevec,
the predominant plasma half-life determined by arodel fitting
Timely thrombolytic therapy using alteplase (recombinant
tissue-type plasminogen activator) during acute myocardial
infarction achieves rapid patency of the infarct-related cor-
onary artery and results in improved survival (1) . Alteplase
is the only thrombolytic agent in clinical use that demon-
strates significani clot selectivity (2) .
The currently recommended alteplase dose in acute myu-
cardial infarction is 100 mg over 3 h, consisting of 10 mg as
an initial intravenous bolus injection, followed by infusions
of 50 mg in the let h and 20 mgJh during the 2nd and 3rd h
(prescribing information, Boehringer Icgelheim (imbH and
Genentech), With this regimen, an angiographically docu-
mented coronary patency rate of 71% after 90 min has
been repeated (31. Mote recently, however, several studies
(4) have been performed with the aim of optimizing further
the dosing of ahleplase . In particular, Neuhaus et a1. (5)
achieved a very high coronary patency rate of 91% at 90 min
using an accelerated "front-loaded" regimen (6). Wi h tats
dosing schedule, 1 W mg was given in 90 min, comprising an
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based on either assay (3.3 to 3.5 min) was unaltered compared
with the standard regimen. Maximal
concentrations
of fihshn
and fibrinogen degradation products were 5.1 i 2.2 and 1 .9 ±
1
.1 fagiml,
respernvely . plasminogen decreased
to 70% and
alpha, antiplasmln to 35 i ( : vaucs befarc hillason.
The results indieatt that I) improved coronary patency rules
during "front-loaded" inludim can be rationalized in terms of
high r plasma concentrations of both free and imnronnereacfnve
alteplase, 2) kinetic variables an comparable with these of other
dosing strateo es, and 3) fibrin specificity is not d®lntshed relative
to that of the standard infusion r4-
Q Am Cull Cordial 1992 ;19:70%7 5)
initial 15-mg intravenous bolus injection, followed by infu-
sions of 50 mg in 30 min and 35 mg in 60 than.
There have been few systematic pharmacokinetic inves-
tigations of the currently marketed preparation of alteplase
in myocardial infarction (7). We recently reported studies
using the standard infusion regimen (9) and a single 50-mg
bolus injection (9) . The aims of the present study were to
measure alteplase plasma concentrations and hemostasis
variables in patients undergoing the accelerated dosing
schedule of Neuhaus et e! . (5), and to assess whether the
in_reased
efficacy
of this regimen can be rationalized in
pharmacokioeric terms- The patients were a subset of a
recent cooperative randomized trial comparing alteplase and
anistreplase with respect to early
coronary artery patency
(10).
Methods
Study patients
. From April 1989 to May [9915 . 10 patients
(9 men and I woman) who were participating at the Gryttin-
gen University Clinic center in the collaborative alteplasel
anistreplase patency study (TAPS) (10) were selected for
additional pharmacokinetic analysis . Inclusion and exclu-
sion criteria were as previously described (10,11) . Patients
randomized to alteplase at this center were sequentially
assigned to the pharmacokinetic study provided that
they
were able, in the clinician's assessment, to tolerate the
additional blood sampling procedures
. The study protocol
07v-IC9791 OS .ao
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was approved by the Review Board of the hospital, and the
patients gave informed consent, which was written or wit-
nessed . The essential baseline characteristics of the patients
were the following: age 56 ± 8 years (range 46 to 69), body
weight 79 ± 12 kg (range 54 to 93), mean time between onset
of symptoms and start of alteplase therapy 2 .5 ± 0.9 h (range
1.3 to 4) .
Administration of alteplase, coronary angingraphy. Al-
teplase (Actilyse, Dr. Karl Thomae GmbH) was adminis-
tered intravenously into a forearm vein of each patient by
means of a controlled-rate infusion pump . Fifteen milligrams
was infused in exactly 2 min to simulate a bolus injection,
followed by 50 mg in 30 min and 35 mg in Warm . All patients
received intravenous heparin; the dose was a 5,000-Iu bolus
injection before administration of alteplase was started,
followed by heparin infusion at a rate that :as adjusted to
maintain the thrombin time 2.5 times higher than the upper
limit of normal. Coronary angiography was an essential
feature of the TAPS study protocol and was performed 60
and 90 min after the start of alteplase infusion . Vessels were
considered patent if their nngiograms corresponded to grade
2 or 3 of the Thrombolysis in Myocardial lniaretion (TIMI)
classification (3).
Blood sampling and assays for alteplase. At baseline and
at 15 additional time points during and after alteplase infu-
sions, two 4-ml blood samples were taken from an untecu-
bital vein in the forearm contralateral to the infusion site,
using disodium ethytenediamine tetraacetic acid (EDTA) as
anticoagulant. The latest sampling time was 24 h after the
initiation of alteplase infusions . To the 1st 4-ml sample,
D-Phe-Pro-Arg-CH2CI (Calbiochem, Frankfurt) was added
to a final concentration of`2 pM to inhibit binding of alteplase
to plasma proteins before measurement using enzyme-linked
immunosorbent assay (ELISA) (12). The second sample,
without added inhibitor, was used to measure alteplase
functional activity. Plasma was prepared within 15 min,
frozen and kept at -20'C until analysis . Alteplase was
measured both as antigen with use of a two-site assay
(ELISA) and as functional activity with use of a chromo-
genic assay that included glu-plasntinogen, cyanogen bro-
mide fragments of fibrinogen and the substrate S-2251
(H-Val-Leu-Lys-para-nitroaniiide)
. Both assay procedures
have been previously described in detail (13,14) . The detec-
tion limits of these assays far alteplase in plasma samples
were 0.3 ne/ad (ELISA) and 3 ng/ml (chromogenic activity) .
Assays for hemostasis variables . At baseline, at 2 or 4 h
and at 24 h after the start of alteplase infusions, further
plasma samples were obtained for measurement of hemosta-
Sit variables . Plasminogen and alpha2 -antiplasmin were de-
termined amidolyticalty with use of chromogenic substrates
and fibrinogen was determined with use of a clotting rate
assay, as described previously (13,14) . Degradation products
of cross-linked fibrin and of fibrinogen were measured with
use of specific monoclonal antibody-based
ELISA methods
(15) that are available commercially as kits (Fibrinostika,
Organon Teknika, The Netheriands) . The detection limit of
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both ELISA methods was 0 .01 gg/ml, and the upper limits of
the normal ranges for healthy persons, as specified by the
manufacturer, were 0 .31 gg/ml for fibrin degradation prod-
ucts and 0.25 pglml for fibrinogen degradation products .
Data analysis . Alteplase plasma concentration-lime pro-
files were fitted for each patient by means of the program
TOPFIT (16) . Baseline alteplasee concentrations, when mea-
surable, were subtracted from all subsequent concentrations
before fitting. The two-compartment model depicted in the
inset to Figure 2 was used, which incorporated elimination
from the central (plasma) compartment, reversible distribu-
tion into one peripherai (tissue) compartment and consecu-
tive zero-order drug inputs (infusions) into the central com-
partment. The following variables were calculated from the
model with standard fornulas (17) : maximal plasma concen-
tration after the 15-mg bolus injection awl steady state
concentrations during the 50- and 35-mg infusions, respec-
tively (Fig . 2); total clearance, plasma half-lives and their
corresponding partial areas under the curve, and the vol-
umes of distribution of the central compartment and at
steady state.
Results are expressed as mean values ± SD unless
otherwise stated. The activity/antigen ratio
of alteplase was
determined for each patient by preparing individual plots of
activity versus antigen over all data points of the plasma
concentration-time profile and determining the slope of the
linear regression line. Other comparisons were performed by
using i tests for paired or unpaired samples,
as appropriate ;
p values < 0.05 were considered significant.
Results
Clinical course. The treatment with alteplase was toler-
ated well by all patients, and no adverse events such as
bleeding occurred . The coronary angiograms obtained
90 min after the start of alteplase infusions revealed a patent
infarct-related artery in 8 of the 10 patients . Comparison of
demographic, pharmncokinetic and hemostasis variables re-
vealed no significant differences between the patient sub-
groups that exhibited a patent or a nonpatent vessel.
Phermacokinetiete The time course of alteplase plasma
concemrations in the patients, measured as antigen and
functional activity, is shown in Figure l . An example of a
pharmacokinetic fit of the data from
one patient is given
in Figure 2, and the mean model-derived variables are
summarized in Table 1
. Alteplase antigen concentrations
in plasma reached a maximum of 4 pg/mi after the 15 mg
bolus injection, maintained an initial
steady state value of
3 .2 pg/ml during the first infusion of 50 mg over 30 min and
decreased to a second steady state of 1 .08 Win] during the
subsequent infusion of 35 mg over 60 min .
Stee4v stare
plasma concentrations based on alteplase
functional activity were approximately 30% lower than an-
tigen concentrations, and therefore the clearance
calculated
from functional activity was correspondingly higher . These
differences were statistically significant (Table 1) . Also, 24 h
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Figure 1. Time course of alteplase plasma concentrations after
accelerated infusions (sgmuesl . Alteplasc was mcasared both as
antigen concentration (closed symbols, lower panel) and functional
activity (open symbols, upper panel) . Data points are shown as mean
values ± SD . For comparison, mean profiles (SD omitted far clarity)
are also shown during the standard infusion schedule (triangles) . for
which the antigen data are derived from reference 8 and the activity
data are new
.
after the start of infusions, alteplase antigen concentrations
were significantly elevated over baseline values, whereas
functional activity at both these time points was below the
assay detection limit .
he time profiles of altepl&e antigen and functional
activiry
daring alreplase llerafy were, however, closely
similar. In particular, alteplase concentrmions measured in
both assays declined biphasically after termination of the
infusions. A rapid alpha-phase with a half-life of 3 .3 to
3.5 min was followed by a longer beta-phase with a half-life
of72 to 88 min, The alpha-phase ofalteplase disposition was
dominant, because it accounted for 85% to 88%
or the area
under the curve, Half-lives and partial areas under the curve
derived from functional activity were not significantly differ-
ent from those based on antigen concentration ; the same was
true for the volumes of distribution of the central compart-
meat and at steady state..
Comparison with standard infusion kinetics. Aheplase
plasma concentration profiles from the standard infusion
regimen are included Fur comparison in Figure 1
. The antigen
values were taken from reference 8; however, functional
activity measurements from the patients ref that study are
reported for the first time here, Initial steady state values
listed in Table I during accelerated infusions were 45% and
51e% higher in terms of antigen concentration and activity,
respectively, than during the standard infusion regimen (p C
0.01) . Second steady state concentmlions were 16% higher
in terms of antigen (p = NS) and 33%n higher for activity
TANSW ELL T7r AL. 1073
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Figure
2. Examples of model fits of alteplase antigen (clessd symw
bola, solid rnrve) and functional activity (npeet ,y®hors, benkee
curve) in plasma sampks from one patient (a 52-year old woman)
; a
and
6
denote the two phases of disposition observed after termina-
tion of the infusions
. Inset
:
two-
: onipartment model used for 4thngz
with the cumpsrtmerds p IplasttraL t (tissue), a (elimination). The
Id
tmnst arrow repteseels the infusion input (1);
the remaining
nerows are first-order Iraosfers of altepkse between the compan-
ments. C .,, = maximal plasma concentration after 15-mg bolus
injection ; C,,,
and C,,,
steady state concentrations during the 50-
and 35-mg infusions . respectively.
(p < 0 .01) . There were no significant differences between the
two regimens with respect to the dominant (alpha) plasma
half-life and the volumes of distribution of the central
compartment and at steady stale; however, total plasma
clearance was significantly more rapid compared with that of
the standard regimen (572 vs
. 380 mImin based an antigen
;
829 vs . 661 mllmin for activity
; p C 0
.001)
.
Table 1 . Alteplase Phann icokinetic Variables After Accelerated
Dosing in 10 Patients With
Acute Myocardial Infarction
Be;aw assay datecrton limit 70tfierea,e between 24h and Baseline
alteplase aedam cmuenlaations
; the reinairing p ,*,s penaia to differences
between antigen andh
.rcnonalactivity . AUC,= partial area ondathca,rn ;
C,,,,,, = aailml plasma coo cvsation after 15-mg balsa joetioa; C„, and
C„ . = steady state ,l-acoecs,hutians dadngthe Se-and 35-mg infusions,
respectively: CL = 1,51
draranee; t,,,, and t,,,, = plasma Wife; V, and
V„ = volumes ordinnhnlmn ofthe cMtm1 compamram aid at sandy stale,
no opt ati arty.
AnIgea
Fmetimnt
Ad.viq p Va.
Baseline coacrnttation logimO 6 .1
r
5 .3 '
Cnncrm,ason at 24 h rngrmn 12 .4 6 a.ma
C,,,, leermn 4 1 2 .9 z 0.81 0,02
C,,, (µ81m0 3 .2 *- 0.84 2.1 10.23 0.006
C,,, (pg/ml) 1 .08 a 0.71 0.7620.11
0.002
CL lest/mint 572 t 132 929- 183 0.001
g
a
, (mina 3.5 ! L4 3.7 ± 0.9 No"
[,,, v
Imin1 72
.
fib 88 n 68 NS
AUC,1%)
85 x 11 a8 19 Ns
V, Oft-)
3 .401 .5 4.4 11 .1 N9
v„tatnsl 8.4 005 9S z5.3 N9
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N=352
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antigen (icy/ml)
Figure 3 . Correlation between alleplase plasma concentrations,
measured as antigen (x axis) and functional activity (y axis), in 10
patients with myocardial infarction . Squares and triangles represent
data from the "aecelerated" and "standard" infos,on regimens,
respectively.
The mean anligenlactiviry railo,
derived from the sholics
of linear regression plots for individual patients, was 0
.65 '_
0 .15 and 0 .72 ± 0.07 for the accelerated and standard
infusion regimens, respectively (p = NS) . On combining the
data for both studies. the graph shown in Figure 3 was
obtained, which yielded an overall activity/antigen ratio for
22 patients of 0 .65 (95%
confidence
limits, range 0.62 to
0 .68) .
Systemic effects . The effects of the accelerated alleplase
infusions on hemostasis variables of the study patients are
depicted in Figure 4 . Mean fibrinogen levels decreased to
61% of baseline by 4 h (p < 0 .001) but had reverted to 81%
at 24 h . The fibrinogen concentration at 4 h was below
0
.5 Miter at 4 h is one patient . Plasminogen and alpha2 -
antiplasmin demonstrated a qualitatively similar time depen-
dence, decreasing to 70% and 35% of preinfusion values,
respectively, al 2 h but rising to 83% and 88%, respectively,
at 24 h. Mean fibrin degradation product values at baseline
(0 .34 ± 0 .19 ng(ml) were slightly above the upper limit of
normal, increased to 5
.1 ± 2 .2 ytelml at 2 h and were still
significantly elevated at 24 h after dosing (0 .59 s 0.16
pig/ml
p = 0 .03) . Fibrinogen degradation products were normal at
baseline (0 .13 ± 0 .19 pglml)
. increased to 19 ± 1 .05 isg)ml at
2 h but were eel significantly different from baseline at 24 h
(0.32 - 0.32 pg)mp .
Discussion
Pharmseokinetics. The principal finding of this clinical
pharmacologic study is that during accelerated infusions,
initial steady siaie plasma concentrations of alteplase were
significantly higher than during the standard infusion sched-
ule. This was the case whether ELISA or the chromogenic
activity assay was used to measure alteplase (Fig
. 1), In this
small subgroup, 8 of l0 patients exhibited a patent infarct-
related coronary artery at 90 min, which is consistent with
c
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4 . Time course of variables of systemic hemostasis during
accelerated infusions of alteplase . FbDP= fibrin degradation prod-
ucts: FgDP = fibrinogen degradation products. Data points are
mean values a SEM .
I Figure
the value of 84%a for all 217 patients treated with alteplase in
the TAPS Study (10) . Therefore, the mean initial steady state
plasma concentrations of 3.1 Aglml (antigen) or 2 .1 µg/ml
(activity) are reasonable estimates of the pharmacologic
plasma concentrations associated with the increased veloc-
ity of coronary thrombolysis previously reported using the
"front-loaded" dosage regimen (5,6,10). The steady state
concentration after the second, maintenance infusion was
only slightly higher after accelerated dosing, and this infu.
sites was of shorter duration than in the standard regimen .
Therefore, the elevated initial plasma concentration of al-
teplase is probably the primary determinant of high early
coronary artery palency . The principal function of the
maintenance infusions is probably the prevention ofreecclw
lion
(t8).
Plasma concentrations of free alteplase measured as
chromogenic activity were 35% lower than values measured
as immuaOreactivt protein using E LISA . in both the accel-
erated and the standard infusion regimens (Fig . I and 3).
This finding confirms and extends data from our earlier
studies in healthy volunteers (13,14) and is consistent with a
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recent report (19) that demonstrated that the discrepancy is
due to complexation of alteplase by plasma protein inhibit ors
such as alpha_-antiplasmin . The domptexes are panialiy
detectable in ;he ELISA but not in the activity assay (13) . A
novel feature of the present stud, is that goad two-
compartment pharmacokinetie model its could be obtained
using plasma concentration-time data from both the actisity
assay and
ELISA in patients with myocardial infarction 1Fig.
21 ; in particular, the hatfdives and volumes of distribution
derived from either analytical method were equivalesr .
Pha7macokinetic variables (Table II were generally in
good agreement with values reported earlier for the star
. rare
infusion regimen (8) or a single W0-mg bolus injection (^) . 1^
particular, the short alpha plasma half-life was in the range
3 .5 to
4 .8
min for all three studies ; however, aite,tave
clearance after accelerated infusions was significantly higher
than during the standard regimen (8) even though the same
assays were used and the paiisuts exhibited similar baseline
characteristics in both studies . Therefore, other yet undeter-
mined factors that influence the elimination of alteplase .
which
morn- . rims'" through specific uptake in the liver
(20) . must be responsible for the difference in clearance .
Fibrin specificity. The effects of accelerated infusions an
hemostasis (Fig. 4) were moderate, 'f
he minor decreases in
plasminogen and fibrinogen, and the significant residual level
of alpha= antiplasmin, indicated that the extent of systemic
plasmin generation was only limited, tabular as bleeding
events are correlated with fibrinogenolysis (21), the data
provide support for the safety of this regimen . The fibrin
specificity
of alteplase was underscored
by the almost three-
fold higher maximal levels of fibrr, degradation as opposed
to fibrinogen degradation products. The results are highly
comparable with the systemic effects observed after the
standard infusion regimen (8) . Fibrinogen degradation prod-
ucts and alteplase antigen were significantly elevated at 24 h
with respect to baseline, which supports the hypothesis that
alteplase exerts prolonged pharmacologic effects despite its
short circulatory half-life (22).
Conclusions . She improved efficacy of the "front-
loaded" infusion scheme for thrombolylic therapy by at-
teplase in myocardial infarction is fully rationvlized by the
pharmacokinetic data obtained in this study aid is attained
without sacrificing fibrin specificity,
we gratefully acknowledge the encdlent technical
assistance
of Susanne
Ziesche in fleuforminf the laboratory trcrl .ri as analyse,
.
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